# Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

> **NCT05132504** · PHASE2 · RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Folfirinox

## Key facts

- **NCT ID:** NCT05132504
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-31
- **Primary completion:** 2027-05-21
- **Final completion:** 2027-05-21
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132504, "Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05132504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*